BIA
MYGN icon

Barry Investment Advisors’s Myriad Genetics MYGN Stock Holding History

Barry Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-8,464
Closed -$259K – 73
2016
Q2 		$259K Sell
8,464
-30
-0.4% -$1.04K 0.1% 59
2016
Q1 		$318K Hold
8,494
– – 0.1% 62
2015
Q4 		$367K Hold
8,494
– – 0.12% 59
2015
Q3 		$318K Sell
8,494
-1,338
-14% -$47.5K 0.1% 62
2015
Q2 		$334K Hold
9,832
– – 0.34% 32
2015
Q1 		$348K Buy
9,832
+28
+0.3% +$1K 0.11% 61
2014
Q4 		$334K Buy
+9,804
New +$348K 0.11% 65

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Barry Investment Advisors's MYGN Position: Q3 2016 in Review

Barry Investment Advisors sold out of Myriad Genetics (MYGN) in Q3 2016, closing a stake of 8,464 shares — an estimated $259K sold.

Barry Investment Advisors first reported a position in MYGN in Q4 2014 and held it in 7 quarters. The position peaked at $367K in Q4 2015. 223 funds tracked by Wall St. Rank hold MYGN as of Q3 2016.

  • Barry Investment Advisors reported no remaining Myriad Genetics position as of Q3 2016 after selling out during the quarter.
  • Barry Investment Advisors sold 8,464 Myriad Genetics shares in Q3 2016, an estimated $259K.
  • Barry Investment Advisors first reported a position in Myriad Genetics in Q4 2014 and held it in 7 quarters.
  • Barry Investment Advisors's Myriad Genetics position peaked at $367K in Q4 2015.
  • 223 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2016.

Based on Barry Investment Advisors's 13F filing for Q3 2016, filed 26 Oct 2016.